Pemvidutide
Chemical compound
From Wikipedia, the free encyclopedia
Pemvidutide is an experimental dual GLP-1/glucagon receptor agonist for the treatment of MASH, obesity, AUD, and ALD developed by Altimmune, a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland.[1][2]
Other namesALT-801; MD-1373; SP-1373
Legal status
- Investigational
| Clinical data | |
|---|---|
| Other names | ALT-801; MD-1373; SP-1373 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C182H275N39O54 |
| Molar mass | 3873.421 g·mol−1 |
The drug reduced LDL-C in a clinical trial[3] and does not require dose titration as with GLP-1 mono agonists.[4] The company's latest Phase 2 trial also showed improvement in MASH combined with significant weight loss.[5]
